Cargando…

Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis?

BACKGROUND: Demyelination diseases are complex puzzles that are not always straightforward to diagnose. Multiple sclerosis and neuromyelitis optica are two that are frequently encountered. Numerous autoantibodies newly discovered in recent years have significantly aided clinical reasoning and diagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Ke, Cheng, Chang, Qin, Chuan, Xiao, Jun, Deng, Gang, Bu, Bi-Tao, Xu, Sha-Bei, Tian, Dai-Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733162/ https://www.ncbi.nlm.nih.gov/pubmed/35003138 http://dx.doi.org/10.3389/fimmu.2021.808420

Ejemplares similares

Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis
por: Chen, Xin, et al.
Publicado: (2023)

The Emerging Role of Microglia in Neuromyelitis Optica
por: Chen, Tingjun, et al.
Publicado: (2021)

Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder
por: Uzonyi, Barbara, et al.
Publicado: (2021)

The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders
por: Häusser-Kinzel, Silke, et al.
Publicado: (2019)

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)

Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice
por: Yick, Leung-Wah, et al.
Publicado: (2018)

Ependyma: a new target for autoantibodies in neuromyelitis optica?
por: Bigotte, Maxime, et al.
Publicado: (2022)

Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder
por: Hu, Yacen, et al.
Publicado: (2022)

Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder
por: Qin, Chuan, et al.
Publicado: (2020)

Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models
por: Luo, Wenqin, et al.
Publicado: (2023)

Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico
por: Zarei, Sara, et al.
Publicado: (2018)

Demyelinating syndrome in systemic sclerosis and neuromyelitis optica
por: Deeb, Khaled, et al.
Publicado: (2019)

Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice
por: Li, Zhiguo, et al.
Publicado: (2018)

Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
por: Ostendorf, Lennard, et al.
Publicado: (2019)

Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders
por: Tzartos, John S., et al.
Publicado: (2013)

Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus
por: Sepulveda, Maria, et al.
Publicado: (2019)

The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases
por: Wang, Xiaofei, et al.
Publicado: (2022)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Aquaporin 4-positive neuromyelitis optica spectrum disorder with meningoencephalitis-like onset: A case report
por: Bu, Yi, et al.
Publicado: (2022)

COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study
por: Sun, Dongren, et al.
Publicado: (2023)

Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: How it influences clinical course, MRI parameters and prognosis
por: Nytrova, Petra, et al.
Publicado: (2022)

The circadian rhythms regulated by Cx43-signaling in the pathogenesis of Neuromyelitis Optica
por: Xue, Huiru, et al.
Publicado: (2023)

Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
por: Miyamoto, Katsuichi, et al.
Publicado: (2023)

Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
por: Wang, Liang, et al.
Publicado: (2022)

Detection of anti-aquaporin-4 autoantibodies in the sera of Chinese neuromyelitis optica patients★
por: Li, Miao, et al.
Publicado: (2013)

Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica
por: Chanson, Jean-Baptiste, et al.
Publicado: (2013)

GRP78 autoantibodies initiate the breakdown of the blood-brain barrier in neuromyelitis optica
por: Shimizu, Fumitaka, et al.
Publicado: (2017)

Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
por: Chen, Bo, et al.
Publicado: (2017)

A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders
por: Tabansky, Inna, et al.
Publicado: (2022)

Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder
por: Du, Chen, et al.
Publicado: (2021)

TREM2 deficiency inhibits microglial activation and aggravates demyelinating injury in neuromyelitis optica spectrum disorder
por: You, Yun-Fan, et al.
Publicado: (2023)

Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder
por: Chang, Haoxiao, et al.
Publicado: (2021)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Neuromyelitis optica and neuroregeneration
Publicado: (2012)

Immunotherapy of Neuromyelitis Optica
por: Bienia, Benjamin, et al.
Publicado: (2013)

Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder
por: Ma, Xue, et al.
Publicado: (2021)

Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
por: Flórez-Grau, Georgina, et al.
Publicado: (2018)

Optical Coherence Tomography in Multiple Sclerosis and Neuromyelitis Optica: An Update
por: Noval, Susana, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lpaqsp91eloc97j1krq7pf48e3